On Tuesday, RBC Capital Markets adjusted its outlook on shares of Editas Medicine (NASDAQ:EDIT), reducing the price target to $5 from the previous $8. The firm has kept its Sector Perform rating on the company's shares. The revision follows Editas Medicine's announcement of a strategic shift, which includes plans to partner or out-license its lead asset for sickle cell disease and beta-thalassemia (SCD/BT), both ex vivo treatments.
The company has decided to concentrate efforts on its in vivo pipeline. Updated data for SCD/BT is expected to be presented at the American Society of Hematology (ASH) meeting, scheduled for December 7-10th. Further developments regarding the in vivo pipeline are anticipated to be shared in the first quarter of 2025.
RBC Capital noted that Editas Medicine has sufficient cash to continue operations into the second quarter of 2026. The firm believes that partnering the SCD/BT program is a sound strategic move, considering the slow market uptake for this class of treatments.
However, the firm remains cautious and is waiting for additional progress on the in vivo pipeline, with the next update expected in the first quarter of 2025. The timing for Investigational New Drug (IND) or Clinical Trial Application (CTA) submissions for the in vivo treatments is still to be determined.
In their commentary, the analyst from RBC Capital reiterated the Sector Perform rating, highlighting the speculative risk associated with the company. The lowered price target to $5 reflects the uncertainties and the recent strategic changes announced by Editas Medicine.
In other recent news, Editas Medicine has seen a series of adjustments in analyst price targets following its Q3 2024 performance report and strategic updates. Barclays (LON:BARC) reduced its target to $5, maintaining an Equalweight rating, while Truist Securities adjusted its target to $8, maintaining a Buy rating. Wells Fargo (NYSE:WFC) revised its target from $27 to $9, maintaining an Overweight rating, and Baird reduced its target to $10 from $18, keeping an Outperform rating.
These adjustments come as Editas Medicine confirms its intention to find partners or out-license its gene-editing candidate, reni-cel (EDIT-301). The company also expects to continue its updates for sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT) at the American Society of Hematology (ASH) 2024 conference.
In the first quarter of 2025, Editas Medicine anticipates providing an update on the progress and development of its in vivo pipeline. The firm has also secured an upfront payment of $57 million from a financing agreement with DRI Healthcare Trust.
These recent developments are part of a larger strategic shift towards its in vivo platform, with a focus on gene editing treatments for sickle cell disease and beta-thalassemia. The company reported high levels of editing in hematopoietic stem and progenitor cells, indicating significant strides in this area.
InvestingPro Insights
Recent InvestingPro data provides additional context to Editas Medicine's financial situation and market performance, aligning with RBC Capital's cautious stance. The company's market capitalization stands at $236.85 million, reflecting its current valuation in the biotech sector.
InvestingPro Tips highlight that Editas is "quickly burning through cash" and "analysts anticipate sales decline in the current year." These insights corroborate RBC Capital's emphasis on the company's cash position and strategic shift. The tip noting that Editas "suffers from weak gross profit margins" is particularly relevant, with InvestingPro data showing a negative gross profit margin of -114.59% for the last twelve months as of Q3 2024.
The company's financial challenges are further underscored by its negative operating income of -$228.52 million and a concerning operating income margin of -317.78% for the same period. These figures align with the InvestingPro Tip that "analysts do not anticipate the company will be profitable this year."
Investors should note that Editas' stock has experienced significant volatility, with the price falling 39.11% over the last three months and 49.21% over the past six months. This performance is consistent with the InvestingPro Tip indicating that the "stock price movements are quite volatile."
For those seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for Editas Medicine, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.